$OBSV News

Last published 3y ago

3y agoOBSVObsEva Files Year End 2022 Financial StatementsGlobeNewswireObsEva Files Year End 2022 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 31, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market: OBSVF), a
3y agoOBSVObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023GlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 15, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN)), a biopharmaceutical company developing and commercializing novel
3y agoOBSVObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in SwitzerlandGlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN)), a biopharmaceutical company developing and commercializing novel
3y agoOBSVObsEva Announces Strategic Reorganization to Consolidate Operations in SwitzerlandGlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 24, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN)), a biopharmaceutical company developing and commercializing novel
3y agoOBSVObsEva Announces Dismissal of Moratorium ProceedingsGlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 19, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN)), a biopharmaceutical company developing and commercializing novel
3y agoOBSVObsEva Evidences Compliance with Nasdaq's Stockholder's Equity Rule and Announces Moratorium Dismissal Request FilingGlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 14, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN)), a biopharmaceutical company developing and commercializing novel
3y agoOBSVObsEva To Increase Issued Share Capital by Creating Additional Treasury SharesGlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 9, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN)), a biopharmaceutical company developing and commercializing novel
3y agoOBSVObsEva Announces Third Quarter 2022 Financial Results and Provides a Business UpdateGlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 1, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN)) ("ObsEva" or the "Company"), a biopharmaceutical company developing
3y agoOBSVObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 MillionGlobeNewswireSale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 millionThe sale proceeds are expected to enable ObsEva to resolve its current
4y agoOBSVObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium ProceedingsGlobeNewswireTransition of linzagolix program to Kissei Pharmaceutical Co., Ltd. substantially complete with approximately $16.0 million savings expected from assignment of program contracts, including $3.7 million of accounts
4y agoOBSVObsEva Announces IND Approval for Yuyuan Bioscience's Phase 1 Clinical Trial of Nolasiban in ChinaGlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – October 13, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN)), a biopharmaceutical company developing novel therapies for women's
4y agoOBSVObsEva Announces Progress on Restructuring InitiativesGlobeNewswire$7.6 million annual savings expected via reduction-in-force currently underway $6.2 million savings expected from assignment of legacy linzagolix program contracts to Kissei Pharmaceutical Co., Ltd., including $1.7 million of accounts payable assigned
4y agoOBSVObsEva Receives Nasdaq Non-Compliance NoticeGlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland and Boston, MA – August 22, 2022 – ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing novel therapies to improve women's reproductive hea
4y agoOBSVObsEva Announces $31 million Debt Retirement and $11 million Debt RefinancingGlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – August 1, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing novel therapies for women's health, today announced the ea
4y agoOBSVObsEva Announces Corporate UpdatesGlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – July 27, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing novel therapies for women's health, today announced tha
4y agoOBSVObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine FibroidsGlobeNewswire-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to receive royalties on commercial sales, as well
4y agoOBSVObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine FibroidsGlobeNewswire-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to receive royalties on commercial sales, as well as d
4y agoOBSVObsEva Announces Corporate UpdatesGlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 27, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health,
4y agoOBSVObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple CongressesGlobeNewswire-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20th World Congress- GENEVA, Switzerland May 25,
4y agoOBSVObsEva Announces Appointment of Annette Clancy as Chair of the Board of DirectorsGlobeNewswireGENEVA, Switzerland May 19, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment of Annette Clancy as Chair of the Board of Directors
4y agoOBSVObsEva SA Announces that Shareholders Approved all Board Proposals at its 2022 Annual General Meeting held on May 18, 2022GlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – May 19, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health,
4y agoOBSV OGNObsEva Announces First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswire-Linzagolix for uterine fibroids: Received confirmation of positive CHMP opinion for marketing authorization application; United States NDA PDUFA date in Q3:22- -Linzagolix for endometriosis: Reported positive topline results for linzagolix 2
4y agoOBSVObsEva to Present at the H.C. Wainwright Global Investment 2022 ConferenceGlobeNewswireGENEVA, Switzerland May 16, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that Company Management will provide a corporate update at the upcom
4y agoOBSVObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business UpdateGlobeNewswireGENEVA, Switzerland – May 12, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it plans to host a conference call on Tuesday, May 17, 2022
4y agoOBSVObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific MeetingGlobeNewswire-Additional data from the PRIMROSE Phase 3 studies of linzagolix featured in four posters. Oral presentation took place on May 8, 2022 at 9:15am PT/12:15pm ET- GENEVA, Switzerland May 9, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biophar
4y agoEVFM OBSV TEVAObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical OfficerGlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today ann
4y agoAMTX ATER INZY OBSV+1Thinking about buying stock in Obseva, Aterian, Inozyme Pharma, Aemetis, or Redbox?PR NewswireNEW YORK, April 26, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OBSV, ATER, INZY, AMTX, and RDBX.
4y agoOBSV SYNHObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine FibroidsGlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 25, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, to
4y agoOBSVObsEva Annual General Meeting 2022GlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland and Boston, MA – April 7, 2022 – ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve
4y agoOBSVObsEva Annual Report 2021GlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland and Boston, MA – March 31, 2022 – ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing and commercializing novel therapies to improv
4y agoOBSVObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated PainGlobeNewswire-Reductions in dysmenorrhea (DYS) and non-menstrual pelvic pain (NMPP), the co-primary efficacy endpoints, compared to placebo were observed for both doses after 1 and 2 months of treatment, respectively, and these reductions increased up to 6 months-
4y agoOBSV OGNObsEva Announces Year End 2021 Financial Results and Provides Corporate UpdateGlobeNewswire-Linzagolix for uterine fibroids: US NDA Q3:22 PDUFA date; Positive CHMP opinion- -Linzagolix for endometriosis: Reported positive topline results for linzagolix 200 mg with add-back therapy in the Phase 3 EDELWEISS 3 trial- -Li
4y agoOBSVObsEva Enters into Licensing Agreement with Theramex for the Commercialization of LinzagolixGlobeNewswire- Partnership leverages Theramex's leading women's health capabilities and commercial infrastructure to support the commercialization and market introduction of linzagolix across global markets outside of the U.S., Canada and Asia - - Linzagolix is an
4y agoOBSVObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine FibroidsGlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 4, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's heal
4y agoASTR CREX NOK OBSV+1Thinking about buying stock in Creative Realities, SoFi Technologies, Obseva SA, Astra Space, or Nokia?PR NewswireNEW YORK, Feb. 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CREX, SOFI, OBSV, ASTR, and NOK. T
4y agoOBSVObsEva Appoints Katja Buhrer as Chief Strategy OfficerGlobeNewswireGENEVA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment of Katja Buhrer as Chief Strategy Officer and
4y agoOBSVObsEva Announces Corporate UpdatesGlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – January 28, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's heal
4y agoOBSVObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated PainGlobeNewswire-Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 months; showed statistically significant and clinically meaningful improvements ver
4y agoOBSVObsEva to Present at the H.C. Wainwright BioConnect 2022 ConferenceGlobeNewswireGENEVA, Switzerland January 3, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that Company Management will provide a corpor
4y agoOBSV NBIObsEva Added to the NASDAQ Biotechnology IndexGlobeNewswireGENEVA, Switzerland December 20, 2021 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced it has been selected for addition to the NA
4y agoBLRX EPAY GNFT OBSV+1Thinking about buying stock in Spruce Biosciences, Bottomline Technologies, BioLine RX, Obseva SA, or Genfit SA?PR NewswireNEW YORK, Dec. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPRB, EPAY, BLRX, OBSV, and GNFT.
4y agoOBSVObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine FibroidsGlobeNewswire-European Commission Decision Anticipated in Q1 2022- -CHMP recommendation follows the recent acceptance of the linzagolix uterine fibroids NDA by the U.S. Food and Drug Administration- Ad hoc announcement pursuant to Art. 53 LR of the SIX
4y agoALT OBSVObsEva Appoints Will Brown as Chief Financial OfficerGlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 13, 2021 – ObsEva SA (NASDAQ:OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's re
4y agoOBSVObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021GlobeNewswire-Symposium on oral GnRH antagonists and personalized therapeutic approaches for women with uterine fibroids to be hosted Friday, December 10 at 1 p.m. CET- -52-Week Data from the Phase 3 PRIMROSE studies of linzagolix for the treatment of uter
4y agoOBSVObsEva Announces Symposium and Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021GlobeNewswireGENEVA, Switzerland December 2, 2021 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced a symposium and three oral presentations on
4y agoOBSVObseva Announces U.S. FDA Acceptance of New Drug Application for LinzagolixGlobeNewswireFDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland November 22, 2021 – Obseva SA (NASDAQ
4y agoOBSVObseva Announces Appointment of Stephanie Brown to its Board of DirectorsGlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland November 22, 2021 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies to improve women's
4y agoBOLT FMTX OBSVBolt Biotherapeutics Announces Changes to its Board of DirectorsGlobeNewswireREDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of bot
5y agoOBSV OGN SYNHObsEva Announces Third Quarter 2021 Financial Results and Business UpdateGlobeNewswire-Linzagolix for uterine fibroids: Pending regulatory approval in the US and Europe with commercial planning efforts underway- -Linzagolix for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21- -Ebopiprant: Global Li
5y agoOBSVObsEva Announces Management ChangeGlobeNewswireAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – October 29, 2021 – ObsEva SA (NASDAQ:OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's repr